Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Lung cancer with MET exon 14 skipping mutation | LCTT
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens | European Respiratory Society
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - Lung Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Lung cancer - The Lancet
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
References in Lung cancer: current therapies and new targeted treatments - The Lancet
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer - Lung Cancer
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Mutational profiles in non-small cell lung cancer. (A) Oncogenic driver... | Download Scientific Diagram
